Episode Details
Back to Episodes
Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC
Description
In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:
- Optimal testing for RET fusions
- DNA NGS vs RNA NGS
- Molecular testing workflows
- Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC
- Common toxicities with new selective RET inhibitors
- Interdisciplinary communication between medical oncologists and pathologists
Presenters:
Dara L. Aisner, MD, PhD
Associate Professor
Department of Pathology
Director, Molecular Pathology
University of Colorado
Aurora, Colorado
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program, including associated downloadable slidesets:
https://bit.ly/2Fsq9Wv
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.